Fenobam

A potent negative allosteric modulator highly selective for mGluR₅ (IC₅₀ = 87 nM; K_d = 54 nM and 31 nM at recombinant mGlu₅ receptors of rat and human, respectively). Biologically active admitted orally or systematically. Frequently used for assessing the functional roles of mGlu₅ receptors in a variety of brain functions (i.e. learning and memory, circadian rhythms, reward and decision making, and locomotion) and disorders (i.e. addition, depression, seizures, anxiety disorder, Parkinson′s disease, Alzheimer′s disease, and Down syndrome). A leading therapeutic candidate for treatment of fragile X syndrome.

Primary Target
mGlu₅ receptors

Target K_i: 54 nM and 31 nM at recombinant mGlu₅ receptors of rat and human, respectively

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Porter, R., et al. 2005. J. Pharmacol. Exp. Ther.315, 711.

Jacob, W., et al. 2009. Neuropharmacology57, 97.
Berry-Kravis, E., et al. 2009. J. Medical Genetics.46, 266.
Watterson, R., et al. 2012. Psychopharmacol.2012, 1.
Simonyi, A., et al. 2010. Eur. J. Pharmacol.639, 17.
Westmark, J., et al. 2010. J. Alzheimer′s Disease20, 1009.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)